Year |
Citation |
Score |
2019 |
Gui B, Gui F, Takai T, Feng C, Bai X, Fazli L, Dong X, Liu S, Zhang X, Zhang W, Kibel AS, Jia L. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proceedings of the National Academy of Sciences of the United States of America. PMID 31266892 DOI: 10.1073/Pnas.1908547116 |
0.338 |
|
2018 |
Huang X, Zhao W, Zhang X, Liu M, Vasconcelos SNS, Zhang W. One-pot Fluorination and Organocatalytic Robinson Annulation for Asymmetric Synthesis of Mono- and Difluorinated Cyclohexenones. Molecules (Basel, Switzerland). 23. PMID 30181479 DOI: 10.3390/molecules23092251 |
0.358 |
|
2018 |
Huang X, Zhao W, Zhang X, Liu M, Vasconcelos SNS, Zhang W. One-pot Fluorination and Organocatalytic Robinson Annulation for Asymmetric Synthesis of Mono- and Difluorinated Cyclohexenones. Molecules (Basel, Switzerland). 23. PMID 30181479 DOI: 10.3390/molecules23092251 |
0.358 |
|
2018 |
Liu S, Yosief HO, Dai L, Huang H, Dhawan G, Zhang X, Muthengi AM, Roberts J, Buckley DL, Perry JA, Wu L, Bradner JE, Qi J, Zhang W. Structure-guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors. Journal of Medicinal Chemistry. PMID 30125504 DOI: 10.1021/Acs.Jmedchem.8B00765 |
0.384 |
|
2017 |
Huang H, Liu S, Jean M, Simpson S, Huang H, Merkley M, Hayashi T, Kong W, Rodríguez-Sánchez I, Zhang X, Yosief HO, Miao H, Que J, Kobie JJ, Bradner J, et al. A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. Frontiers in Microbiology. 8: 1035. PMID 28638377 DOI: 10.3389/Fmicb.2017.01035 |
0.332 |
|
2017 |
Huang H, Liu S, Jean M, Simpson S, Huang H, Merkley M, Hayashi T, Kong W, Rodríguez-Sánchez I, Zhang X, Yosief HO, Miao H, Que J, Kobie JJ, Bradner J, et al. A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. Frontiers in Microbiology. 8: 1035. PMID 28638377 DOI: 10.3389/Fmicb.2017.01035 |
0.332 |
|
2016 |
Zhang X, Pham K, Liu S, Legris M, Muthengi A, Jasinski JP, Zhang W. Stereoselective synthesis of fused tetrahydroquinazolines through one-pot double [3 + 2] dipolar cycloadditions followed by [5 + 1] annulation. Beilstein Journal of Organic Chemistry. 12: 2204-2210. PMID 27829928 DOI: 10.3762/Bjoc.12.211 |
0.381 |
|
2016 |
Zhang X, Pham K, Liu S, Legris M, Muthengi A, Jasinski JP, Zhang W. Stereoselective synthesis of fused tetrahydroquinazolines through one-pot double [3 + 2] dipolar cycloadditions followed by [5 + 1] annulation. Beilstein Journal of Organic Chemistry. 12: 2204-2210. PMID 27829928 DOI: 10.3762/Bjoc.12.211 |
0.381 |
|
2016 |
Huang X, Liu M, Pham K, Zhang X, Yi W, Jasinski JP, Zhang W. Organocatalytic One-pot Asymmetric Synthesis of Thiolated Spiro-gamma-lactam-oxindoles Bearing Three Stereocenters. The Journal of Organic Chemistry. PMID 27258150 DOI: 10.1021/Acs.Joc.6B00653 |
0.352 |
|
2016 |
Huang X, Liu M, Pham K, Zhang X, Yi W, Jasinski JP, Zhang W. Organocatalytic One-pot Asymmetric Synthesis of Thiolated Spiro-gamma-lactam-oxindoles Bearing Three Stereocenters. The Journal of Organic Chemistry. PMID 27258150 DOI: 10.1021/Acs.Joc.6B00653 |
0.352 |
|
2016 |
Yang G, Buhrlage S, Tan L, Liu X, Chen J, Xu L, Tsakmaklis N, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, Cohen P, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. PMID 27143257 DOI: 10.1182/Blood-2016-01-695098 |
0.309 |
|
2016 |
Yang G, Buhrlage S, Tan L, Liu X, Chen J, Xu L, Tsakmaklis N, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, Cohen P, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. PMID 27143257 DOI: 10.1182/Blood-2016-01-695098 |
0.309 |
|
2014 |
McKeown MR, Shaw DL, Fu H, Liu S, Xu X, Marineau JJ, Huang Y, Zhang X, Buckley DL, Kadam A, Zhang Z, Blacklow SC, Qi J, Zhang W, Bradner JE. Biased multicomponent reactions to develop novel bromodomain inhibitors. Journal of Medicinal Chemistry. 57: 9019-27. PMID 25314271 DOI: 10.1021/Jm501120Z |
0.695 |
|
2014 |
McKeown MR, Shaw DL, Fu H, Liu S, Xu X, Marineau JJ, Huang Y, Zhang X, Buckley DL, Kadam A, Zhang Z, Blacklow SC, Qi J, Zhang W, Bradner JE. Biased multicomponent reactions to develop novel bromodomain inhibitors. Journal of Medicinal Chemistry. 57: 9019-27. PMID 25314271 DOI: 10.1021/Jm501120Z |
0.695 |
|
Show low-probability matches. |